QualityDipStocks / Health Care · Medical instruments
Kestra Medical Technologies KMTS
Outside our quality screen, so we don’t track its dips. It’s 3% below its 52-week high.
Outside our quality screen, 9% over its Market Value. No fair value estimate for now: its free cash flow is negative.
Worth knowing
- Revenue up 61% in a year, top 5% of the 2194 we measure
From the data on this page, as of the last close. How we pick these
- Fair value est.
- n/a
- Market Value
- $27.30price +9%
- Off 52-wk high
- −3%
- Risk vs market
- Highbeta 1.50
52-week range 94% of the way from its 52-week low to its high
Price $29.81Market Value $27.30
5 bullish · 5 bearish See why
Repriced or dip?
Near its high
The price is 3% below its 52-week high (Oct 29), but the business held up: net cash (cash minus debt) 0.0% of market cap since the high, operating margin 0.0 pts.
Some numbers held up (net cash (cash minus debt) 0.0% of market cap since the high, operating margin 0.0 pts), others slipped. The price is 3% below its 52-week high.
The price is 3% below its 52-week high, and the business changed too.
Within 10% of its 52-week high, so there is no dip to judge yet.
Data-based read, not advice.
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for KMTS: negative free cash flow. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much KMTS moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Swings much more than the market, and its own price swings are 5.0× the S&P 500’s.
- Beta vs S&P 500
- 1.50
- Volatility
- 64% vs 13% SPY
- Correlation SPY
- 0.30
- Correlation QQQ
- 0.23
How it ranks
Where KMTS stands vs every one of the 2,467 stocks we cover that has the number. Longer bar = better.
Top quarter on 1 of 5 measures
- Free cash flow yield−6.8% · free cash flow vs market capLowest 6%of 1,690
- Dividends + buybacks yield0% · cash paid out or used to retire shares, vs market capLowest 1%of 2,227
- Revenue growth, last 12 months+61% · vs the 12 months beforeTop 5%of 2,184
- Operating margin−134% · of sales kept as operating profitLowest 1%of 1,549
- Return on invested capital−118% · profit per dollar of capitalLowest 1%of 1,001
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
MV $27.30
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 5 of 5
GrowthSales grew 61% to $107M over the last 12 months vs the 12 months before (SEC filings).
ProfitabilityGross margin widened to 51.4% in FY2026 from 1.3% in FY2024 (SEC filings).
ProfitabilityOperating margin widened to −141.6% in FY2026 from −305.8% in FY2024 (SEC filings).
GrowthSales compounded 85% a year from FY2024 to FY2026.
Balance sheetNet cash of $126M: cash and short-term investments exceed debt (Jul 31, 2026).
Top bearish points 5 of 5
ValuationFree cash flow is negative (−$123M over the last 12 months), so there’s no cash-flow value under the price.
Balance sheetOperating income covers interest only -19.0× over the last 12 months.
ProfitabilityLost $150M over the last 12 months (net income, SEC filings).
Cash returnsShare count up 14.2% in a year: existing holders are being diluted.
QualityDoesn’t pass our quality screen: no positive free cash flow; ROE under 12% and ROIC under 10%.
All fundamentals
FCF yield -6.8% · ROE -74% · Sales +61%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/anegative free cash flow
- FCF yield
- −6.8%
- EV / EBITDA
- n/anegative EBITDA
- Price / sales
- 16.87×
- Price / book
- 8.10×
- Market cap
- $1.8Blisted
- Enterprise value
- $1.7B
Growth
- Revenue, 12 months
- $107M
- Sales growth, 12 months
- +60.7%vs the 12 months before
- Sales growth, 3 yrs
- +84.9%/yrfrom FY2024
- Diluted EPS, 12 months
- −$2.68
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$150M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- 53.9%
- Operating margin
- −134.5%
- Net margin
- −140.4%
- FCF margin
- −115.0%
- Return on equity
- −74%
- Return on invested capital
- −118%
Balance sheet
- Cash & short-term inv.
- $199M
- Total debt
- $72M
- Net cash
- $126M
- Debt / equity
- 0.33×
- Interest coverage
- -19.0×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- −$123M
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- +14.2%diluted shares vs a year ago
- Stock-based comp
- $39M
Trailing 12 months to Jul 31, 2026; balance sheet at Jul 31, 2026. From Kestra Medical Technologies’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $-0.1B · Sales +60%
- Free cash flow, 12 months−$0.1B
- Free-cash-flow yield-6.8%
- Gross margin54%
- Operating margin−122%
- Return on invested capital−101%
- Return on equity−74%
- Sales growth (latest quarter vs year-ago quarter)+60%
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $29.81
- 52-wk lowlowest close, 1 year$17.87−40.1%
- Market Valueavg paid since Sep 14$27.30−8.4%
- PriceMon Nov 2 close$29.81you are here
- 52-wk highhighest close, 1 year$30.61+2.7%
Momentum & 52-week range
RSI 58 · 5 days +1.3%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
KMTS is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Kestra Medical Technologies in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 5:14 PM ET.
Compare with peers
Closest in size in Medical instruments
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.